GLP

GLP Capital Partners closes inaugural commingled clean energy strategy with RMB 4 billion in commitments

Retrieved on: 
Tuesday, August 8, 2023
Wind, Renewable energy, GLP, Maintenance, GCP, EV, Carbon

SHANGHAI and SINGAPORE , Aug. 7, 2023 /PRNewswire/ -- GLP Capital Partners ("GCP") has established its first commingled clean energy strategy in China, raising approximately RMB 4 billion in total capital commitments from domestic institutions including National Green Development Fund and feeder funds affiliated with CHN Energy Investment Group, one of China's largest electricity providers and a prominent state-owned enterprise in the energy sector. The overall investment of the fund is expected to reach approximately RMB 20 billion.

Key Points: 
  • The overall investment of the fund is expected to reach approximately RMB 20 billion.
  • The capital raised provides dry powder for renewable energy investments across wind, solar, energy storage infrastructure and related energy management solutions and the fund will target both greenfield projects and acquisitions in these sectors.
  • "This is a significant fundraise for GCP and we are pleased to raise third-party capital from partners who share the same vision for strengthening renewable energy investment," said Teresa Zhuge, Executive Vice Chairman and President, China at GLP Capital Partners.
  • "Renewable energy is one of GLP's key pillars, focusing on facilitating the energy transition across new economy sectors for a sustainable future.

GLP Capital Partners closes inaugural commingled clean energy strategy with RMB 4 billion in commitments

Retrieved on: 
Tuesday, August 8, 2023
Wind, Renewable energy, GLP, Maintenance, GCP, EV, Carbon

SHANGHAI and SINGAPORE, Aug. 8, 2023 /PRNewswire/ -- GLP Capital Partners ("GCP") has established its first commingled clean energy strategy in China, raising approximately RMB 4 billion in total capital commitments from domestic institutions including National Green Development Fund and feeder funds affiliated with CHN Energy Investment Group, one of China's largest electricity providers and a prominent state-owned enterprise in the energy sector. The overall investment of the fund is expected to reach approximately RMB 20 billion.

Key Points: 
  • The overall investment of the fund is expected to reach approximately RMB 20 billion.
  • The capital raised provides dry powder for renewable energy investments across wind, solar, energy storage infrastructure and related energy management solutions and the fund will target both greenfield projects and acquisitions in these sectors.
  • "This is a significant fundraise for GCP and we are pleased to raise third-party capital from partners who share the same vision for strengthening renewable energy investment," said Teresa Zhuge, Executive Vice Chairman and President, China at GLP Capital Partners.
  • "Renewable energy is one of GLP's key pillars, focusing on facilitating the energy transition across new economy sectors for a sustainable future.

Signati™️ Medical, Inc. Announces Dr. LeRoy Jones Has Been Appointed to Its Board of Directors

Retrieved on: 
Thursday, August 3, 2023
GLP, Society, Vasectomy, Private practice, LSU, Publication, FDA, Dentistry, Medical device, Birth control, Sixtus Signati

Providence, RI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Signati™️ Medical, Inc. announced today that Dr. LeRoy Jones has been appointed to its Board of Directors.

Key Points: 
  • Providence, RI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Signati™️ Medical, Inc. announced today that Dr. LeRoy Jones has been appointed to its Board of Directors.
  • Dr. Jones is considered an authority in the field of sexual medicine, having performed over 3000 prosthetic surgeries.
  • Dr. Jones is internationally recognized and has taught surgery in over 26 countries throughout the world.
  • Dr. Jones is currently in private practice with Urology San Antonio in San Antonio, Texas.

Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results

Retrieved on: 
Thursday, August 3, 2023
GLP, HD, GBA1, Gene, Ataxia, HTT, Conference call, Disease, Telephone, Neurocrine Biosciences, Neurocrine, TRACER, G&A, Huntington's disease, Research, Brain, CNS, Small RNA, SOD1, Novartis, Prion, FXN, MSH3, Annual general meeting, Cell, Toxicology, Mouse, Sirna Therapeutics, Growth, FDA, Therapy, ALS, IND, Neurology, Conference, Society, Sangamo Therapeutics, VY, D, Vaccine, Pharmaceutical industry, Fine chemical, Cryptocurrency, Voyager

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported second quarter 2023 financial and operating results.

Key Points: 
  • ET today -
    CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported second quarter 2023 financial and operating results.
  • Collaboration Revenues: Voyager had collaboration revenue of $4.9 million for the second quarter of 2023, compared to $0.7 million for the same period in 2022.
  • The increase was primarily due to revenue recognized during the second quarter of 2023 on the 2023 and 2019 strategic collaborations with Neurocrine Biosciences.
  • ET to discuss the second quarter 2023 financial and operating results.

uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Tuesday, August 1, 2023
Senior, Takeda, Abbott Laboratories, CSL, American Society of Gene and Cell Therapy, Associate, Research and development, Development, Patient, Cell, Toxicology, Fabry disease, ALS, Gene, General counsel, Research, Forma, SOD1, Corporation, CSF, Wells Fargo, IND, Unified, Conference, Safety, GLP, Abstract, Natural history, CSL Behring, Cancer, AAV, Primate, Therapy, Takeda Pharmaceutical Company, Commercialization, AFL, Clinical trial, Sale, Novartis, Takeda Oncology, Novo Nordisk, Immunosuppression, Society, Pharmaceutical industry, Cryptocurrency, EU, Pfizer

and AMSTERDAM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2023 and highlighted recent progress across its business.

Key Points: 
  • and AMSTERDAM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2023 and highlighted recent progress across its business.
  • The Company continues to make progress enrolling the second, high-dose cohort of nine patients and expects to complete enrollment in the third quarter of 2023.
  • The Company expects to initiate a Phase I/II clinical study of AMT-162 in the second half of 2023.
  • The Company expects cash, cash equivalents and investment securities will fund operations into the second quarter of 2026.

Metrion Biosciences Announces Launch of Good Laboratory Practice (GLP) hERG Screening Service

Retrieved on: 
Tuesday, August 1, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, GLP, Human, Therapy, HERG, Health care, ICH, HTS, Kingdom of Poland, Investigational New Drug, Electrophysiology, Good laboratory practice, Drug discovery, UK, IND, CIPA, MHRA, Pharmaceutical industry, Mobile phone

GLP hERG screening is a vital step in the transition from preclinical research to Phase 1 clinical trials in humans, regardless of therapeutic target class.

Key Points: 
  • GLP hERG screening is a vital step in the transition from preclinical research to Phase 1 clinical trials in humans, regardless of therapeutic target class.
  • Metrion has offered hERG profiling services since the Company was founded in 2015 and has since expanded its cardiac safety offer to include a full panel of Comprehensive in Vitro Proarrhythmia Assay (CiPA) services.
  • Addition of the new GLP hERG service further strengthens the Company’s suite of cardiac safety screening assays, providing a substantial range of options to assess potential cardiac liabilities as preclinical discovery research programmes are progressed.
  • Dr Andrew Southan, Chief Executive of Metrion Biosciences, said: “The launch of our GLP hERG screening capability adds further depth to our ion channel drug discovery services and complements our existing cardiac safety service portfolio.

Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop

Retrieved on: 
Monday, July 17, 2023
HSV, GLP, Human, Assembly, Bio, Biotechnology, Pharmacokinetics, Viral, Doctor of Philosophy, Plasma, SAN, Toxicology, Vaccine, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced data from development candidate ABI-5366, a long-acting herpes simplex virus (HSV) helicase inhibitor targeting high-recurrence genital herpes, featured in one oral and one poster presentation at the 47th Annual International Herpesvirus Workshop in Missoula, Montana, taking place July 15-19, 2023.

Key Points: 
  • Additionally, in multiple preclinical models, oral dosing or subcutaneous injection of ABI-5366 demonstrated sustained plasma concentrations for greater than one month.
  • The presentations also include non-GLP safety data available to date supporting a favorable safety profile for ABI-5366 with high exposure margins and minimal potential for off-target effects.
  • Assembly Bio plans to initiate a Phase 1a study for ABI-5366 in the first half of 2024.
  • Subsequent to presentation at the International Herpesvirus Workshop, Assembly Bio intends to make the oral presentation and poster available on the “Events & Presentations” page in the “Investors” section of its website at www.assemblybio.com .

Struct Finance Transforms DeFi Landscape on Avalanche With the Launch of Tranche-based BTC.B-USDC Vaults

Retrieved on: 
Wednesday, July 12, 2023
wBTC, GLP, Liquidity, WisdomTree Investments, GMX, USDC, BlackRock, Commonwealth of Australia (US securities entity), Decentralized finance, Avalanche, WBTC, Risk, Invesco, Interest rate, BTC, Cryptocurrency, Bitcoin

In its ongoing journey to reshape the crypto investing landscape, Struct Finance, a DeFi platform that enables investors to engage with tailored interest rate products linked to digital assets, is thrilled to announce the launch of the BTC.B-USDC Vaults.

Key Points: 
  • In its ongoing journey to reshape the crypto investing landscape, Struct Finance, a DeFi platform that enables investors to engage with tailored interest rate products linked to digital assets, is thrilled to announce the launch of the BTC.B-USDC Vaults.
  • The tranche-based BTC.B-USDC Interest Rate Product was made possible by effectively leveraging Avalanche’s BTC.B (Bridged Bitcoin) for DeFi applications.
  • The new vault beautifully complements Struct Finance’s Genesis USDC Vaults, heralding an exciting era in DeFi yield opportunities.
  • As part of its BTC.B-USDC Vaults, Struct Finance has implemented a unique approach to managing investment risk: delta hedging.

Laboratory Information Management System (LIMS) Market worth $3.3 billion | MarketsandMarkets

Retrieved on: 
Friday, July 7, 2023
GLP, ISO, Laboratory information management system, Overalls, LabLynx, LabVantage, ATL, Thermo Fisher Scientific, ERP, Forecasting, Dassault Group, CDS, Data analysis, Integrity, Investment, Computer security, Risk, Laboratory, Quality control, Agilent Technologies, Porter's five forces analysis, Knowledge, Growth, Data, LIMS, Biomax Informatics, Good laboratory practice, Acquisition, Medical tourism, Recession, ELN, Calibration, LabWare, Video game, Fine chemical, Retail, Medical device, Audit, Instrumentation

The cloud-based segment is expected to register a substantial growth in the laboratory information management systems market, by deployment mode

Key Points: 
  • The cloud-based segment is expected to register a substantial growth in the laboratory information management systems market, by deployment mode
    The cloud-based segment is expected to register a substantial growth in the laboratory information management systems market, by deployment mode.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=250610373
    Laboratory Information Management System (LIMS) Market Advantages:
    Data Centralization and Organization: LIMS provides a centralized platform for storing, managing, and organizing laboratory data.
  • In summary, the Laboratory Information Management System (LIMS) market offers advantages such as data centralization, streamlined workflows, increased efficiency, quality control, enhanced data analysis, scalability, integration capabilities, and data security.
  • Market Overview: This edition includes updated market dynamics and market ecosystems specific to the laboratory information management systemsmarket.

Laboratory Information Management System (LIMS) Market worth $3.3 billion | MarketsandMarkets

Retrieved on: 
Friday, July 7, 2023
GLP, ISO, Laboratory information management system, Overalls, LabLynx, LabVantage, ATL, Thermo Fisher Scientific, ERP, Forecasting, Dassault Group, CDS, Data analysis, Integrity, Investment, Computer security, Risk, Laboratory, Quality control, Agilent Technologies, Porter's five forces analysis, Knowledge, Growth, Data, LIMS, Biomax Informatics, Good laboratory practice, Acquisition, Medical tourism, Recession, ELN, Calibration, LabWare, Video game, Fine chemical, Retail, Medical device, Audit, Instrumentation

The cloud-based segment is expected to register a substantial growth in the laboratory information management systems market, by deployment mode

Key Points: 
  • The cloud-based segment is expected to register a substantial growth in the laboratory information management systems market, by deployment mode
    The cloud-based segment is expected to register a substantial growth in the laboratory information management systems market, by deployment mode.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=250610373
    Laboratory Information Management System (LIMS) Market Advantages:
    Data Centralization and Organization: LIMS provides a centralized platform for storing, managing, and organizing laboratory data.
  • In summary, the Laboratory Information Management System (LIMS) market offers advantages such as data centralization, streamlined workflows, increased efficiency, quality control, enhanced data analysis, scalability, integration capabilities, and data security.
  • Market Overview: This edition includes updated market dynamics and market ecosystems specific to the laboratory information management systemsmarket.